Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
Background Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efficacy of ibrutinib combined with companion drugs for advanced renal cell carcinoma (RCC), gastric/gastroesophageal junctional adenocarcinoma (GC), and colorectal adenocarcinoma (CRC) were evaluated. Methods Ibrutinib 560 mg or 840 mg once daily was administered with standard doses of everolimus for RCC, docetaxel for GC, and cetuximab for CRC. Endpoints included determination of the recommended phase 2 dose (RP2D) of ibrutinib in phase 1b and efficacy (overall response rate [ORR] for GC and CRC; progression-free survival [PFS] for CRC) in phase 2. Results A total of 39 (RCC), 46 (GC), and 50 (RCC) patients were enrolled and received the RP2D. Safety profiles were consistent with the individual agents used in the study. Confirmed ORRs were 3% (RCC), 21% (GC), and 19% (CRC). Median (90% CI) PFS was 5.6 (3.9–7.5) months in RCC, 4.0 (2.7–4.2) months in GC, and 5.4 (4.1–5.8) months in CRC. Conclusions Clinically meaningful increases in efficacy were not observed compared to historical controls; however, the data may warrant further evaluation of ibrutinib combinations in other solid tumours. Trial registration ClinicalTrials.gov, NCT02599324..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC cancer - 23(2023), 1 vom: 03. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Oh, Do-Youn [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Cetuximab |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12885-023-11539-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053611721 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053611721 | ||
| 003 | DE-627 | ||
| 005 | 20231103064638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231103s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-023-11539-1 |2 doi | |
| 035 | |a (DE-627)SPR053611721 | ||
| 035 | |a (SPR)s12885-023-11539-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Oh, Do-Youn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efficacy of ibrutinib combined with companion drugs for advanced renal cell carcinoma (RCC), gastric/gastroesophageal junctional adenocarcinoma (GC), and colorectal adenocarcinoma (CRC) were evaluated. Methods Ibrutinib 560 mg or 840 mg once daily was administered with standard doses of everolimus for RCC, docetaxel for GC, and cetuximab for CRC. Endpoints included determination of the recommended phase 2 dose (RP2D) of ibrutinib in phase 1b and efficacy (overall response rate [ORR] for GC and CRC; progression-free survival [PFS] for CRC) in phase 2. Results A total of 39 (RCC), 46 (GC), and 50 (RCC) patients were enrolled and received the RP2D. Safety profiles were consistent with the individual agents used in the study. Confirmed ORRs were 3% (RCC), 21% (GC), and 19% (CRC). Median (90% CI) PFS was 5.6 (3.9–7.5) months in RCC, 4.0 (2.7–4.2) months in GC, and 5.4 (4.1–5.8) months in CRC. Conclusions Clinically meaningful increases in efficacy were not observed compared to historical controls; however, the data may warrant further evaluation of ibrutinib combinations in other solid tumours. Trial registration ClinicalTrials.gov, NCT02599324. | ||
| 650 | 4 | |a Renal cell carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Gastric adenocarcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Colorectal carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ibrutinib |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Everolimus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Docetaxel |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cetuximab |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Maqueda, Maria Alsina |4 aut | |
| 700 | 1 | |a Quinn, David I. |4 aut | |
| 700 | 1 | |a O’Dwyer, Peter J. |4 aut | |
| 700 | 1 | |a Chau, Ian |4 aut | |
| 700 | 1 | |a Kim, Sun Young |4 aut | |
| 700 | 1 | |a Duran, Ignacio |4 aut | |
| 700 | 1 | |a Castellano, Daniel |4 aut | |
| 700 | 1 | |a Berlin, Jordan |4 aut | |
| 700 | 1 | |a Mellado, Begona |4 aut | |
| 700 | 1 | |a Williamson, Stephen K. |4 aut | |
| 700 | 1 | |a Lee, Keun-Wook |4 aut | |
| 700 | 1 | |a Marti, Francisca |4 aut | |
| 700 | 1 | |a Mathew, Paul |4 aut | |
| 700 | 1 | |a Saif, Muhammad Wasif |4 aut | |
| 700 | 1 | |a Wang, Ding |4 aut | |
| 700 | 1 | |a Chong, Elizabeth |4 aut | |
| 700 | 1 | |a Hilger-Rolfe, Jacqueline |4 aut | |
| 700 | 1 | |a Dean, James P. |4 aut | |
| 700 | 1 | |a Arkenau, Hendrik-Tobias |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 23(2023), 1 vom: 03. Nov. |w (DE-627)SPR027602656 |w (DE-600)2041352-X |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:03 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12885-023-11539-1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 03 |c 11 | ||